Can Gilead Change Its Dim Fortunes On An Immuno-Oncology Buyout?

Can Gilead Change Its Dim Fortunes On An Immuno-Oncology Buyout?

Source: 
Investors Business Daily
snippet: 

Gilead Sciences (GILD) is attempting to alter its fortunes through the $4.9 billion acquisition of immuno-oncology biotech company Forty Seven (FTSV).

But analysts are split on whether the massive effort will be enough to outstrip an ongoing decline in Gilead sales over the past half-decade. The company has yet to reverse a steady decline in Gilead stock, though investors have shown an interest in the biotech giant again in recent days.